5.11
0.44 (9.42%)
| Previous Close | 4.67 |
| Open | 4.65 |
| Volume | 525,171 |
| Avg. Volume (3M) | 247,516 |
| Market Cap | 210,519,584 |
| Price / Sales | 97.52 |
| Price / Book | 165.91 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Operating Margin (TTM) | -3,917.27% |
| Diluted EPS (TTM) | -3.47 |
| Quarterly Revenue Growth (YOY) | -27.40% |
| Total Debt/Equity (MRQ) | 4.68% |
| Current Ratio (MRQ) | 3.67 |
| Operating Cash Flow (TTM) | -67.20 M |
| Levered Free Cash Flow (TTM) | -48.03 M |
| Return on Assets (TTM) | -135.31% |
| Return on Equity (TTM) | -263.65% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Bearish | |
| Stock | Anteris Technologies Global Cor | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 1.0 |
| Average | 0.00 |
|
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Value |
| % Held by Insiders | 0.21% |
| % Held by Institutions | 64.12% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Rhenman & Partners Asset Management Ab | 30 Sep 2025 | 1,250,763 |
| 52 Weeks Range | ||
| Median | 16.00 (213.11%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 11 Mar 2026 | 16.00 (213.11%) | Buy | 6.20 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 22 Jan 2026 | Announcement | Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises |
| 22 Jan 2026 | Announcement | Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock |
| 20 Jan 2026 | Announcement | Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering |
| 20 Jan 2026 | Announcement | Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |